Compare iShares MSCI South Korea ETF (EWY) vs NeoGenomics Inc. Common Stock (NEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs NeoGenomics Inc. Common Stock — how do they compare? iShares MSCI South Korea ETF trades at $150.18 (market cap $22.66B), while NeoGenomics Inc. Common Stock trades at $17 (market cap $2.17B). The key difference: iShares MSCI South Korea ETF is far larger — about 10.4× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 48 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| EWY | NEO | |
|---|---|---|
Market Cap | $22.66B | $2.17B |
Volume | 17,900,400 | 1,615,943 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $19.91 |
52-Week Low | $85.17 | $7.19 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $2.47B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →
